GeneDx reported second-quarter 2026 revenue of $114.4 million and GAAP net loss of $17.7 million, while adjusted net income was $0.4 million. Exome and genome revenue reached $100.3 million with result volumes up 32% year-over-year; adjusted gross margin was approximately 70%. The company reaffirmed full-year 2026 revenue guidance of $475–$490 million and reiterated at least 30% exome and genome volume growth for the year.

Financial Highlights

  • Total revenue: $114.4 million for Q2 2026.
  • Exome and genome revenue: $100.3 million for Q2 2026.
  • GAAP gross margin: 68%; adjusted gross margin: 70% in Q2 2026.
  • GAAP net loss: $17.7 million for Q2 2026; adjusted net income: $0.4 million for Q2 2026.
  • Cash, cash equivalents, marketable securities and restricted cash: $133.5 million as of June 30, 2026; pro forma cash position ~ $188 million after amended loan and private placement on August 3, 2026.

Business Highlights

  • Exome and genome test result volume: 30,785 in Q2 2026, a 32% year-over-year increase.
  • Management changes: Mark Gardner appointed President to lead commercial and operations teams to support scaling and execution.
  • Product and customer experience improvements: launched redesigned exome and genome reports to better serve non-genetics clinicians and rolled out broader CX enhancements.
  • Coverage expansion: new Texas Medicaid exome coverage (effective May 1, 2026); California Medi‑Cal genome pricing at 100% of Medicare rate (effective July 1, 2026); Carelon outpatient genome sequencing coverage effective June 14, 2026; Mississippi Medicaid added outpatient exome and genome coverage effective July 1, 2026—bringing state Medicaid programs covering outpatient exome/genome to 39.
  • Scientific and clinical engagement: contributed to 26 peer-reviewed publications, 41 conference presentations, and 50 abstracts in H1 2026.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.